314 related articles for article (PubMed ID: 26010498)
1. Substituted Bis-THF Protease Inhibitors with Improved Potency against Highly Resistant Mature HIV-1 Protease PR20.
Agniswamy J; Louis JM; Shen CH; Yashchuk S; Ghosh AK; Weber IT
J Med Chem; 2015 Jun; 58(12):5088-95. PubMed ID: 26010498
[TBL] [Abstract][Full Text] [Related]
2. Extreme multidrug resistant HIV-1 protease with 20 mutations is resistant to novel protease inhibitors with P1'-pyrrolidinone or P2-tris-tetrahydrofuran.
Agniswamy J; Shen CH; Wang YF; Ghosh AK; Rao KV; Xu CX; Sayer JM; Louis JM; Weber IT
J Med Chem; 2013 May; 56(10):4017-27. PubMed ID: 23590295
[TBL] [Abstract][Full Text] [Related]
3. GRL-0519, a novel oxatricyclic ligand-containing nonpeptidic HIV-1 protease inhibitor (PI), potently suppresses replication of a wide spectrum of multi-PI-resistant HIV-1 variants in vitro.
Amano M; Tojo Y; Salcedo-Gómez PM; Campbell JR; Das D; Aoki M; Xu CX; Rao KV; Ghosh AK; Mitsuya H
Antimicrob Agents Chemother; 2013 May; 57(5):2036-46. PubMed ID: 23403426
[TBL] [Abstract][Full Text] [Related]
4. Design of HIV protease inhibitors targeting protein backbone: an effective strategy for combating drug resistance.
Ghosh AK; Chapsal BD; Weber IT; Mitsuya H
Acc Chem Res; 2008 Jan; 41(1):78-86. PubMed ID: 17722874
[TBL] [Abstract][Full Text] [Related]
5. C-5-Modified Tetrahydropyrano-Tetrahydofuran-Derived Protease Inhibitors (PIs) Exert Potent Inhibition of the Replication of HIV-1 Variants Highly Resistant to Various PIs, including Darunavir.
Aoki M; Hayashi H; Yedidi RS; Martyr CD; Takamatsu Y; Aoki-Ogata H; Nakamura T; Nakata H; Das D; Yamagata Y; Ghosh AK; Mitsuya H
J Virol; 2015 Nov; 90(5):2180-94. PubMed ID: 26581995
[TBL] [Abstract][Full Text] [Related]
6. Potent antiviral HIV-1 protease inhibitor combats highly drug resistant mutant PR20.
Kneller DW; Agniswamy J; Ghosh AK; Weber IT
Biochem Biophys Res Commun; 2019 Oct; 519(1):61-66. PubMed ID: 31474336
[TBL] [Abstract][Full Text] [Related]
7. Resilience to resistance of HIV-1 protease inhibitors: profile of darunavir.
Lefebvre E; Schiffer CA
AIDS Rev; 2008; 10(3):131-42. PubMed ID: 18820715
[TBL] [Abstract][Full Text] [Related]
8. GRL-02031, a novel nonpeptidic protease inhibitor (PI) containing a stereochemically defined fused cyclopentanyltetrahydrofuran potent against multi-PI-resistant human immunodeficiency virus type 1 in vitro.
Koh Y; Das D; Leschenko S; Nakata H; Ogata-Aoki H; Amano M; Nakayama M; Ghosh AK; Mitsuya H
Antimicrob Agents Chemother; 2009 Mar; 53(3):997-1006. PubMed ID: 18955518
[TBL] [Abstract][Full Text] [Related]
9. GRL-079, a Novel HIV-1 Protease Inhibitor, Is Extremely Potent against Multidrug-Resistant HIV-1 Variants and Has a High Genetic Barrier against the Emergence of Resistant Variants.
Delino NS; Aoki M; Hayashi H; Hattori SI; Chang SB; Takamatsu Y; Martyr CD; Das D; Ghosh AK; Mitsuya H
Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29463535
[TBL] [Abstract][Full Text] [Related]
10. Potent new antiviral compound shows similar inhibition and structural interactions with drug resistant mutants and wild type HIV-1 protease.
Wang YF; Tie Y; Boross PI; Tozser J; Ghosh AK; Harrison RW; Weber IT
J Med Chem; 2007 Sep; 50(18):4509-15. PubMed ID: 17696515
[TBL] [Abstract][Full Text] [Related]
11. Multi-drug resistance profile of PR20 HIV-1 protease is attributed to distorted conformational and drug binding landscape: molecular dynamics insights.
Chetty S; Bhakat S; Martin AJ; Soliman ME
J Biomol Struct Dyn; 2016; 34(1):135-51. PubMed ID: 25671669
[TBL] [Abstract][Full Text] [Related]
12. A Modified P1 Moiety Enhances In Vitro Antiviral Activity against Various Multidrug-Resistant HIV-1 Variants and In Vitro Central Nervous System Penetration Properties of a Novel Nonpeptidic Protease Inhibitor, GRL-10413.
Amano M; Salcedo-Gómez PM; Zhao R; Yedidi RS; Das D; Bulut H; Delino NS; Sheri VR; Ghosh AK; Mitsuya H
Antimicrob Agents Chemother; 2016 Dec; 60(12):7046-7059. PubMed ID: 27620483
[TBL] [Abstract][Full Text] [Related]
13. Binding of Clinical Inhibitors to a Model Precursor of a Rationally Selected Multidrug Resistant HIV-1 Protease Is Significantly Weaker Than That to the Released Mature Enzyme.
Park JH; Sayer JM; Aniana A; Yu X; Weber IT; Harrison RW; Louis JM
Biochemistry; 2016 Apr; 55(16):2390-400. PubMed ID: 27039930
[TBL] [Abstract][Full Text] [Related]
14. A novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI), GRL-98065, is potent against multiple-PI-resistant human immunodeficiency virus in vitro.
Amano M; Koh Y; Das D; Li J; Leschenko S; Wang YF; Boross PI; Weber IT; Ghosh AK; Mitsuya H
Antimicrob Agents Chemother; 2007 Jun; 51(6):2143-55. PubMed ID: 17371811
[TBL] [Abstract][Full Text] [Related]
15. Enhanced stability of monomer fold correlates with extreme drug resistance of HIV-1 protease.
Louis JM; Tözsér J; Roche J; Matúz K; Aniana A; Sayer JM
Biochemistry; 2013 Oct; 52(43):7678-88. PubMed ID: 24079831
[TBL] [Abstract][Full Text] [Related]
16. GRL-04810 and GRL-05010, difluoride-containing nonpeptidic HIV-1 protease inhibitors (PIs) that inhibit the replication of multi-PI-resistant HIV-1 in vitro and possess favorable lipophilicity that may allow blood-brain barrier penetration.
Salcedo Gómez PM; Amano M; Yashchuk S; Mizuno A; Das D; Ghosh AK; Mitsuya H
Antimicrob Agents Chemother; 2013 Dec; 57(12):6110-21. PubMed ID: 24080647
[TBL] [Abstract][Full Text] [Related]
17. GRL-09510, a Unique P2-Crown-Tetrahydrofuranylurethane -Containing HIV-1 Protease Inhibitor, Maintains Its Favorable Antiviral Activity against Highly-Drug-Resistant HIV-1 Variants in vitro.
Amano M; Miguel Salcedo-Gómez P; Yedidi RS; Delino NS; Nakata H; Venkateswara Rao K; Ghosh AK; Mitsuya H
Sci Rep; 2017 Sep; 7(1):12235. PubMed ID: 28947797
[TBL] [Abstract][Full Text] [Related]
18. Novel HIV PR inhibitors with C4-substituted bis-THF and bis-fluoro-benzyl target the two active site mutations of highly drug resistant mutant PR
Agniswamy J; Kneller DW; Ghosh AK; Weber IT
Biochem Biophys Res Commun; 2021 Aug; 566():30-35. PubMed ID: 34111669
[TBL] [Abstract][Full Text] [Related]
19. Novel Central Nervous System (CNS)-Targeting Protease Inhibitors for Drug-Resistant HIV Infection and HIV-Associated CNS Complications.
Amano M; Salcedo-Gómez PM; Yedidi RS; Zhao R; Hayashi H; Hasegawa K; Nakamura T; Martyr CD; Ghosh AK; Mitsuya H
Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 31061155
[TBL] [Abstract][Full Text] [Related]
20. Disubstituted Bis-THF Moieties as New P2 Ligands in Nonpeptidal HIV-1 Protease Inhibitors (II).
Hohlfeld K; Wegner JK; Kesteleyn B; Linclau B; Unge J
J Med Chem; 2015 May; 58(9):4029-38. PubMed ID: 25897791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
